CalciMedica files for up to $25 million at-the-market stock offering
The clinical-stage biotech filed a prospectus supplement on September 30, 2026 to sell shares through H.C. Wainwright & Co. under an existing sales agreement.
SEC filing
Latest
3 stories
Wednesday, September 30
Wednesday, August 19
CalciMedica stockholders back plan increase, reverse split, and warrant issuances at annual meeting
The August 19, 2026 vote covered eight proposals, including a 7,500,000-share bump to the equity incentive plan and a reverse stock split ratio of up to 1-for-10.
SEC filing
Tuesday, August 11
CalciMedica reports Q2 2026 results, advances pulmonary hypertension and pancreatitis programs
Company points to a June private placement of up to $49 million, an FDA-aligned Phase 2b design in acute pancreatitis, and mid-2027 targets for PAH data and a CM5480 IND.
SEC filing